Abstract:Abstract Aims Hepatic venous pressure gradient (HVPG) is the gold standard for the diagnosis and staging of portal hypertension. Previous studies have shown that it underestimates pre-sinusoidal portal hypertension. Endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) can safely measure direct portal vein pressure (PVP) and bridge this diagnostic gap. However, EUS-PPG has so far been performed with patients under deep sedation which can alter HVPG measurement and lead to misclassification of portal hypertension. Ketamine, a conscious sedation agent, has minimal effect on portal hemodynamics. We present our center’s experience with EUS-PPG under ketamine and low dose midazolam. Methods We retrospectively reviewed consecutive patients undergoing EUS-PPG with conscious sedation using ketamine and low-dose midazolam (<0.02 mg/kg) at the McGill University Health Centre from February to May 2021. Patients were placed in the left lateral position. Hepatic vein and portal vein were located through EUS via a trans-gastric/hepatic approach. A through the scope 25-gauge needle attached to a manometer was advanced through the liver to measure hepatic vein pressure (HVP) and portal vein pressure (PVP). Three measurements were sampled per vessel and mean pressure differences calculated to obtain PPG. PPG was considered reliable if the differences between the values was no more than 1mmHg. Results Three patients underwent EUS-PPG for evaluation of pre-sinusoidal portal hypertension. Cirrhosis was excluded in all patients based on recent liver biopsy or transient elastography. The first patient is a 69-year-old man with splenomegaly and recanalization of the paraumbilical vein on imaging. He received 80 mg of ketamine and no midazolam. HVPG measured was 1 mmHg. EUS-PPG was successful with PPG of 6 mmHg (HVP= 7 mmHg, and PVP= 13 mmHg). The second patient is a 42-year-old woman with previous sleeve gastrectomy and known with portal cavernoma. She received 120 mg of ketamine and 1 mg of midazolam. EUS-PPG was technically difficult due to respiratory movements. The measurement was not considered reliable as differences in PPG were as high as 2mmHg. In this case, PPG was 0mmHg (HVP= 15mmHg, and PVP= 15mmHg). The third patient, a 74-year-old man with hepatic steatosis and splenomegaly received 70 mg of ketamine and 1 mg of midazolam. EUS-PPG was successful (HVP= 3mmHg, PVP= 3mmHg) yielding a PPG 0mmHg. All patients tolerated the procedure well with no procedural or sedation-related complications Conclusions Our early experience suggests that EUS-PPG can be successfully and safely performed in patients under conscious sedation with ketamine and low-dose midazolam. This combination may avoid deep sedation with high dose midazolam or propofol which are known to alter accuracy of HVPG. Measurement of HVP (left) and PVP (right) Funding Agencies None

Endoscopic Ultrasound-guided Portal Pressure Gradient Measurement is Technically Successful and Safe Without Deep Sedation: A Proof-of-Concept Case Series

A110 FEASIBILITY OF EUS-GUIDED PORTAL PRESSURE GRADIENT MEASUREMENT WITHOUT DEEP SEDATION: A PATH TO ACCURATE PORTAL PRESSURE DETERMINATION

S4071 Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement Accurately and Safely Streamlines Patient Care

EUS-guided Portal Pressure Gradient Measurement in Patients with Acute or Subacute Portal Hypertension.

Su1227 EUS-GUIDED PORTAL PRESSURE GRADIENT IS CONSISTENT WITH HEPATIC VENOUS PRESSURE GRADIENT IN PATIENTS WITH HEPATIC SINUSOIDAL OBSTRUCTIVE SYNDROME

EUS-Guided Portal Pressure Gradient Measurement in Patients with Portal Hypertension: Evidence-Based Case Report

Endoscopic ultrasound-guided portal pressure gradient measurement in managing portal hypertension

Endoscopic ultrasound-guided portal pressure gradient with liver biopsy: 6 years of endo-hepatology in practice

Endoscopic ultrasound guided portal pressure gradient: safety aspects, clinical relevance and technical issues to improve the procedure

Endoscopic ultrasound-guided portal pressure gradient measurement: a pilot animal study

Technique innovation of endoscopic ultrasound portal pressure gradient measurement using standard manometer set for portal hypertension assessment

Invasive and Non-invasive Diagnosis of Portal Hypertension in Cirrhosis

Interventions for Portal Hypertension: Hepatic Vein Pressure Gradient and Trans Jugular Liver Biopsy

Noninvasive Assessment of Portal Hypertension by Ultrasonography

Non-invasive Assessment of Hepatic Venous Pressure Gradient (HVPG) Based on MR Flow Imaging and Computational Fluid Dynamics

Tolerance and acceptance of hepatic venous pressure gradient measurement in cirrhosis (CHESS1904): An international multicenter study

Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein

Quantitative evaluation of portal pressure by contrast enhanced ultrasonography

Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond

Contrast‐Enhanced Sonography for Quantitative Assessment of Portal Hypertension in Patients with Liver Cirrhosis

Hepatic venous pressure gradient evaluates the Scheuer stage of liver fibrosis by transjugular liver biopsy: a multicenter study